Proto Labs
PRLB
93.27
-4.01
-4.12%
Proto Labs
US · PRLB
#2685 by market cap
Listed 1970
93.27
-4.01
-4.12%
Live - 5344 symbols - heartbeat 29s ago
· 2026-10-08 07:00
Pre-market
93.00
-0.29%
After-hours
93.27
0.00%
- Market cap
- 2.23B
- P/E (TTM)i
- 74.02
- P/Bi
- 3.23
- EPSi
- 0.88
- Div yieldi
- 0.00%
- 52W posi
- 88%
Reader sentiment
Are you bullish or bearish on PRLB?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Good
- Altman Z-Score is 16.48, above the 3.0 "safe zone" threshold.
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 8 years
Latest year +6.44% YoY
Margins
- Gross margin
- 44.48%
- Operating margin
- 4.91%
- Net margin
- 3.98%
Key ratios & quality
- Altman Z-Scorei
- 16.48
Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 445.60M | 458.73M | 434.40M | 488.10M | 488.40M | 503.88M | 500.89M | 533.13M |
| Gross profit | 238.68M | 235.29M | 217.83M | 222.69M | 215.47M | 221.99M | 223.20M | 237.14M |
| Selling & admin expenses | 121.05M | 122.74M | 121.05M | 138.11M | 150.30M | 153.48M | 156.41M | 168.13M |
| Research & development | 28.74M | 32.69M | 36.94M | 44.24M | 38.22M | 40.14M | 41.30M | 42.81M |
| Operating profit | 88.90M | 79.86M | 59.84M | 40.34M | 26.95M | 28.38M | 25.50M | 26.20M |
| Pretax profit | 91.66M | 81.19M | 62.95M | 40.18M | -97.88M | 27.95M | 24.67M | 31.06M |
| Tax | 15.07M | 17.54M | 12.08M | 6.81M | 5.59M | 10.73M | 8.08M | 9.82M |
| Net profit | 76.59M | 63.66M | 50.87M | 33.37M | -103.46M | 17.22M | 16.59M | 21.24M |
| Basic EPS | 3 | 2 | 2 | 1 | -4 | 1 | 1 | 1 |
| Diluted EPS | 2.81 | 2.35 | 1.89 | 1.21 | -3.77 | 0.66 | 0.66 | 0.88 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | 126.21M | 135.06M | 135.37M | 136.49M | 139.34M | 149.34M |
| Gross profit | 55.70M | 59.77M | 61.29M | 60.37M | 63.59M | 69.34M |
| Selling & admin expenses | 40.60M | 43.48M | 41.74M | 42.31M | 41.79M | 45.33M |
| Research & development | 10.61M | 11.17M | 10.71M | 10.32M | 10.54M | 10.79M |
| Operating profit | 4.49M | 5.12M | 8.85M | 7.74M | 11.26M | 13.22M |
| Pretax profit | 5.99M | 6.67M | 10.25M | 8.15M | 11.32M | 12.60M |
| Tax | 2.39M | 2.25M | 3.04M | 2.15M | 3.21M | 3.45M |
| Net profit | 3.60M | 4.43M | 7.22M | 6.00M | 8.11M | 9.15M |
| Basic EPS | 0 | 0 | 0 | 0 | 0 | 0 |
| Diluted EPS | 0.15 | 0.18 | 0.30 | 0.25 | 0.33 | 0.37 |
Balance sheet
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 215.36M | 236.42M | 242.00M | 183.49M | 186.57M | 200.66M | 194.85M | 233.54M |
| Cash & ST investments | 131.80M | 160.66M | 161.69M | 77.51M | 80.13M | 102.80M | 103.09M | 128.12M |
| Inventory | 10.09M | 10.08M | 10.86M | 13.16M | 13.58M | 13.66M | 12.31M | 14.40M |
| Total assets | 618.99M | 673.67M | 744.20M | 928.58M | 802.17M | 772.35M | 743.51M | 763.42M |
| Total current liabilities | 52.73M | 47.58M | 50.25M | 54.90M | 71.58M | 49.68M | 53.27M | 67.00M |
| Short-term debt | -- | 3.34M | 3.82M | 3.85M | 19.10M | 1.88M | 1.60M | 1.44M |
| Long-term debt | -- | -- | -- | -- | -- | -- | -- | -- |
| Total liabilities | 77,488,000.00 | 87,877,000.00 | 99,848,000.00 | 100,089,000.00 | 104,520,000.00 | 77,058,000.00 | 73,361,000.00 | 89,483,000.00 |
| Total equity | 541.50M | 585.79M | 644.36M | 828.49M | 697.65M | 695.30M | 670.15M | 673.93M |
| Retained earnings | 291.46M | 324.72M | 362.90M | 376.73M | 258.24M | 256.40M | 244.41M | 240.76M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 194.41M | 205.51M | 225.79M | 233.54M | 248.58M | 266.24M |
| Cash & ST investments | 96.85M | 103.19M | 119.24M | 128.12M | 136.28M | 142.78M |
| Inventory | 13.20M | 13.17M | 14.07M | 14.40M | 14.87M | 15.41M |
| Total assets | 737.45M | 743.25M | 756.86M | 763.42M | 778.57M | 791.30M |
| Total current liabilities | 62.09M | 62.16M | 69.74M | 67.00M | 70.72M | 73.20M |
| Short-term debt | 1.44M | 1.30M | 1.26M | 1.44M | 1.24M | 1.06M |
| Long-term debt | -- | -- | -- | -- | -- | -- |
| Total liabilities | 80,649,000.00 | 78,545,000.00 | 92,136,000.00 | 89,483,000.00 | 95,442,000.00 | 99,565,000.00 |
| Total equity | 656.80M | 664.71M | 664.72M | 673.93M | 683.13M | 691.73M |
| Retained earnings | 236.55M | 239.34M | 238.57M | 240.76M | 248.88M | 254.33M |
Cash flow
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 122.93M | 116.05M | 106.97M | 55.24M | 62.08M | 73.27M | 77.83M | 74.50M |
| Depreciation & amortization | 26.75M | 30.86M | 32.59M | 40.49M | 39.43M | 37.53M | 35.81M | 33.81M |
| Free cash flow | 35.83M | 53.82M | 59.96M | 21.03M | 40.39M | 45.16M | 68.66M | 59.66M |
| Dividends paid | -- | -- | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | -14.37M | -36.01M | -18.13M | -21.64M | -27.39M | -41.55M | -58.25M | -40.06M |
| Ending cash balance | 85.05M | 125.23M | 127.60M | 65.93M | 56.56M | 83.79M | 89.07M | 110.83M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | 18.38M | 10.58M | 29.09M | 16.45M | 17.54M | 15.44M |
| Depreciation & amortization | 8.69M | 8.57M | 8.43M | 8.12M | 8.07M | 8.09M |
| Free cash flow | 17.12M | 9.12M | 25.03M | 8.40M | 14.00M | 9.24M |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | -21.85M | -5.25M | -12.75M | -206.00K | 737.00K | -11.72M |
| Ending cash balance | 82.69M | 90.38M | 104.42M | 110.83M | 123.97M | 127.92M |
Returns & efficiency
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| ROE %i | 15.28 | 11.29 | 8.27 | 4.53 | -13.56 | 2.47 | 2.43 | 3.16 |
| ROA %i | 13.46 | 9.85 | 7.18 | 3.99 | -11.96 | 2.19 | 2.19 | 2.82 |
| ROIC %i | 15.28 | 11.06 | 8.10 | 4.47 | -13.31 | 2.43 | 2.41 | 3.15 |
| 5-year avg ROE %i | 14.56 | 13.33 | 11.85 | 10.34 | 5.16 | 2.60 | 0.83 | -0.19 |
| EBIT margin %i | 19.95 | 17.41 | 13.77 | 8.27 | 5.52 | 5.63 | 5.09 | 4.91 |
| FCF / sales %i | 8.04 | 11.73 | 13.80 | 4.31 | 8.27 | 8.96 | 13.71 | 11.19 |
| Current ratioi | 4.08 | 4.97 | 4.82 | 3.34 | 2.61 | 4.04 | 3.66 | 3.49 |
| Quick ratioi | 3.73 | 4.58 | 4.38 | 2.89 | 2.24 | 3.58 | 3.24 | 3.13 |
| Debt / assetsi | 0.00 | 1.77 | 1.79 | 0.80 | 2.66 | 0.71 | 0.47 | 0.40 |
| LT debt / equityi | -- | 1.46 | 1.48 | 0.43 | 0.32 | 0.52 | 0.29 | 0.24 |
| Interest coveragei | -- | -- | -- | -- | -- | -- | -- | -- |
| Revenue CAGR (3Y) %i | 19.05 | 15.46 | 8.04 | 3.08 | 2.11 | 5.07 | 0.87 | 2.96 |
| Net income CAGR (3Y) %i | 18.08 | 14.23 | -0.59 | -24.19 | -- | -30.31 | -20.78 | -- |
| FCF CAGR (3Y) %i | 21.99 | 7.04 | 6.88 | -16.27 | -9.12 | -9.02 | 48.34 | 13.88 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | 2.22 | 2.19 | 2.21 | 3.16 | 3.84 | 4.49 |
| ROA %i | 1.98 | 1.97 | 1.96 | 2.82 | 3.40 | 3.97 |
| ROIC %i | 2.21 | 2.18 | 2.20 | 3.15 | 3.83 | 4.48 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | 4.64 | 4.38 | 4.35 | 4.91 | 6.04 | 7.33 |
| FCF / sales %i | 13.43 | 12.96 | 13.06 | 11.19 | 10.35 | 10.11 |
| Current ratioi | 3.13 | 3.31 | 3.24 | 3.49 | 3.51 | 3.64 |
| Quick ratioi | 2.76 | 2.93 | 2.89 | 3.13 | 3.15 | 3.27 |
| Debt / assetsi | 0.43 | 0.38 | 0.32 | 0.40 | 0.34 | 0.28 |
| LT debt / equityi | 0.26 | 0.23 | 0.18 | 0.24 | 0.20 | 0.17 |
| Interest coveragei | -- | -- | -- | -- | -- | -- |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
✦ Quant Revenue Concentration how this is computed
Lead segment, long tail
- Computer numerical control (CNC) Machining is the largest reported line at 47.11% of revenue, across 5 reported segments.
- Injection Molding follows at 35.91%, so the top line still matters most but isn’t the whole story.
Revenue breakdown most recent period
Business
Computer numerical control (CNC) Machining47.11%
Injection Molding35.91%
Three-dimensional (3D) Printing13.84%
Sheet Metal2.99%
Other revenue0.15%
Quote time 2026-10-08 07:00:14 · For reference only, not investment advice and not tailored to your situation.